AnaptysBio (NASDAQ:ANAB) Stock Rating Lowered by BTIG Research

AnaptysBio (NASDAQ:ANAB) was downgraded by investment analysts at BTIG Research from a “buy” rating to a “neutral” rating in a research report issued on Monday, MarketBeat reports.

Other equities research analysts also recently issued reports about the stock. Guggenheim lifted their price objective on shares of AnaptysBio from $75.00 to $90.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. JPMorgan Chase & Co. cut their price objective on shares of AnaptysBio from $75.00 to $66.00 and set an “overweight” rating for the company in a report on Tuesday, November 12th. UBS Group boosted their target price on shares of AnaptysBio from $23.00 to $33.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 30th. HC Wainwright cut their target price on shares of AnaptysBio from $55.00 to $52.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. Finally, Truist Financial boosted their price target on shares of AnaptysBio from $20.00 to $30.00 and gave the stock a “hold” rating in a research report on Thursday, August 15th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $54.64.

AnaptysBio Stock Performance

Shares of NASDAQ:ANAB opened at $22.00 on Monday. The firm has a market cap of $669.46 million, a PE ratio of -3.62 and a beta of -0.11. The firm’s 50 day simple moving average is $27.65 and its 200-day simple moving average is $29.72. AnaptysBio has a one year low of $14.70 and a one year high of $41.31.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.72) by $0.58. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The firm had revenue of $30.02 million for the quarter, compared to the consensus estimate of $7.92 million. Equities research analysts predict that AnaptysBio will post -6.02 EPS for the current fiscal year.

Insider Activity

In related news, insider Paul F. Lizzul sold 1,500 shares of the company’s stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $38.67, for a total transaction of $58,005.00. Following the sale, the insider now directly owns 15,398 shares of the company’s stock, valued at $595,440.66. This represents a 8.88 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Eric J. Loumeau sold 8,720 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $39.82, for a total transaction of $347,230.40. Following the sale, the insider now directly owns 7,020 shares in the company, valued at approximately $279,536.40. The trade was a 55.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 22,440 shares of company stock valued at $892,936. Company insiders own 33.70% of the company’s stock.

Institutional Investors Weigh In On AnaptysBio

Large investors have recently added to or reduced their stakes in the business. Virtu Financial LLC purchased a new stake in shares of AnaptysBio in the 1st quarter valued at approximately $222,000. Assenagon Asset Management S.A. increased its position in shares of AnaptysBio by 38.2% in the 2nd quarter. Assenagon Asset Management S.A. now owns 306,633 shares of the biotechnology company’s stock valued at $7,684,000 after purchasing an additional 84,795 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of AnaptysBio by 16.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 74,510 shares of the biotechnology company’s stock valued at $1,867,000 after purchasing an additional 10,423 shares during the last quarter. Rhumbline Advisers increased its position in shares of AnaptysBio by 1.8% in the 2nd quarter. Rhumbline Advisers now owns 29,715 shares of the biotechnology company’s stock valued at $745,000 after purchasing an additional 525 shares during the last quarter. Finally, TD Asset Management Inc increased its position in shares of AnaptysBio by 67.3% in the 2nd quarter. TD Asset Management Inc now owns 37,800 shares of the biotechnology company’s stock valued at $947,000 after purchasing an additional 15,200 shares during the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.